Related Experiment Video
Updated: Nov 7, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.4K
Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics
Jiyoung Ahn1, Yusung Choi2, Eric Lawrence Simpson3
1Department of Dermatology, National Medical Center, Seoul, Korea.
Annals of Dermatology
|April 29, 2021
Summary
Atopic dermatitis (AD) involves complex immune pathways beyond Th2 dominance, with new research driving innovative small molecule and biologic therapies. Understanding these pathways is crucial for developing effective treatments to manage AD and improve patient quality of life.
Area of Science:
- Immunology
- Dermatology
- Translational Research
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by immune dysregulation and skin barrier defects.
- Recent research challenges the traditional view of AD as solely Th2-dominant, revealing roles for other immune pathways.
Purpose of the Study:
- To explore the evolving understanding of atopic dermatitis pathogenesis.
- To highlight the impact of new insights on therapeutic innovation in AD treatment.
Main Methods:
- Review of current translational research in AD.
- Analysis of immune pathway activation (Th1, Th2, Th17, Th22) in AD patients.
- Investigation of cytokine and chemokine roles, including IL-4, IL-13, IL-31, and IL-22.
Main Results:
- Evidence suggests involvement of Type 1, Type 22, and Type 17 pathways in AD.
- Elevated levels of Type 2 (IL-4, IL-13), IL-31, and Type 22 (IL-22) cytokines are observed in acute AD lesions.
- IL-22 contributes to epidermal hyperplasia and increased S100 gene expression in acute AD.
Conclusions:
- The understanding of AD pathogenesis is expanding beyond Th2 dominance.
- This evolving knowledge fuels innovation in novel therapeutics, including small molecules and biologics.
- Addressing the heterogeneity and chronic nature of AD necessitates safer and more effective treatments to improve patient outcomes.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
261
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
261
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
277
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277
01:28Drug Products: Biologics, Biosimilars and Interchangeables
70
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
70
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
302
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
302
01:19Clinical Applications of Epidermal Stem Cells
3.0K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.0K